Baricitinib Dose Reduction Maintains Disease Control in Rheumatoid Arthritis
New long-term study data suggest that patients with rheumatoid arthritis who achieve sustained disease control on baricitinib 4 mg may successfully taper to 2 mg, with the majority maintaining low disease activity or recapturing control if needed.